研製包覆靛氰綠與喜樹鹼之 HER2 標靶全氟碳雙層奈米乳劑 用於乳癌光/化學治療之研究;Development of HER2 Target Indocyanine Green- Camptothecin-Encapsulated Perfluorocarbon Double- Nanoagentsfor Photochemotherapy of Breast Cancer

NCU Institutional Repository > 生醫理工學院 > 生物醫學工程研究所 > 博碩士論文 > Item 987654321/85832

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.lib.ncu.edu.tw/handle/987654321/85832

题名:	研製包覆靛氰綠與喜樹鹼之 HER2 標靶全氟碳雙層奈米乳劑用於乳癌光/化學治療之研究;Development of HER2 Target Indocyanine Green- Camptothecin-Encapsulated Perfluorocarbon Double- Nanoagentsfor Photochemotherapy of Breast Cancer
作者:	陳俊儒;Chen, Chun-Ju
贡献者:	生醫科學與工程學系
关键词:	乳腺癌;HER2;靛氰綠;喜樹鹼;全氟化合物;奈米試劑;光化學療法
日期:	2021-09-14
上传时间:	2021-12-07 11:31:42 (UTC+8)
出版者:	國立中央大學
摘要:	乳腺癌是女性中發生率最高的癌症。一般而言，由於乳腺癌具有侵襲性強、預後差、復發率高…等特性，早期發現並結合標靶治療以及化療，是可以有效地降低復發的風險，然而抗癌藥物引起的副作用嚴重干擾了患者的生理狀況，甚至可能因此對治療效果產生不利影響。因此我們的目標是通過標靶治療實現對乳腺癌的有效治療，並且可以減少化療藥物的使用。在本次研究中，我們開發了一種包覆靛氰綠(ICG)與喜樹鹼(CPT)之HER2標靶全氟碳雙層奈米乳劑(HER2 target ICG-CPT-encapsulated perfluorocarbon double-nanoagents; HICPDNAs)，可以在光照下同時提供化療以及光療。根據奈米粒徑及介面電位量測儀的分析結果，HICPDNAs 的粒徑和表面電位分別為 268.6 ± 20 nm 和 -25.7 ± 5 mV。ICG和CPT的包覆率分別為 97.842 ± 1.540% 和 46.400 ± 5.780%。與游離的ICG水溶液相比，在近紅外光(NIR)照射下（808 nm, 6 W/cm2），HICPDNAs表現出與游離的ICG水溶液相似的熱療效果，但是卻能夠顯著性地增加單態氧的生成量，顯示出HICPDNAs在光熱和光動力治療應用中具有十足的潛力。在體外細胞實驗中，HICPDNAs表現出了與兩種HER2陽性乳癌細胞的專一性(MDA-MB-453以及BT-474)，並且在細胞毒性的試驗中，也表現出比游離的CPT溶液更好的毒殺效果。在動物試驗中，包覆ICG與CPT之全氟碳雙層奈米乳劑(ICG- CPT-encapsulated perfluorocarbon double-nanoagents; ICPDNAs)表現出比游離的CPT溶液以及僅包埋ICG之奈米粒子(ICG-encapsulated perfluorocarbon double-nanoagents; IPDNAs)組別更好的腫瘤抑制效果，並且對於其他重要的臟器並沒有造成嚴重之傷害。在本次的研究中，我們證明了ICPDNAs對於乳癌之治療是有效的，並且在動物體中也擁有足夠之安全性，顯示出ICPDNAs有望在未來有更進一步的發展。;Breast cancer is the most diagnosed cancer in women. In general, patients with breast cancer have high aggression, poor prognosis, and high recurrence rate. Based on the previous research efforts, treatment by early detection with target chemotherapy may effectively reduce the risk of recurrence. However, anticancer drug-induced side effects seriously interfere the physiological conditions of the patients and may adversely affect the therapeutic efficacy consequently. Therefore, we aim to achieve effective treatment for breast cancer through a target therapy with reduced the use of chemo-drugs. In this study, we have developed a type of HER2 target indocyanine green (ICG)-camptothecin (CPT)-encapsulated perfluorocarbon double-nanoagents (HICPDNAs) that may provide both chemotherapy and phototherapy upon light illumination. Through DLS analysis, the size and zeta potential of the HICPDNAs is about 2268.6 ± 20 nm and -25.7 ± 5 mV, respectively. The encapsulation efficiency for ICG and CPT is 97.842 ± 1.540% and 46.400 ± 5.780%, respectively. In comparison to freely dissolved ICG, the HICPDNAs with equal dose of ICG under near infrared (NIR) irradiation (808 nm, 6 W/cm2) can generate similar hyperthermia effect but significantly enhanced amount of singlet oxygen, showing a high potential for use in photothermal and photodynamic therapeutic applications. In the in vitro cell experiment, HICPDNAs showed specificity with two HER2-positive breast cancer cells (MDA-MB-453 and BT-474)，and in the cytotoxicity test, it also showed a better toxic effect than the free CPT solution. In the animal experiments, ICG-CPT-encapsulated perfluorocarbon double-nanoagents (ICPDNAs) showed better tumor suppression effects than the free CPT solution and ICG particles groups (ICG-encapsulated perfluorocarbon double-nanoagents; IPDNAs). ICPDNAs also didn’t cause serious damage to other important organs in the animal experiments. In this study, we have proved that ICPDNAs are effective in the treatment of breast cancer and have sufficient safety in animals, showing that ICPDNAs is expected to have further development in the future.
显示于类别:	[生物醫學工程研究所 ] 博碩士論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	98	检视/开启

在NCUIR中所有的数据项都受到原著作权保护.

社群 sharing

数据加载中.....